Role of radiation therapy for retroperitoneal sarcomas: An eight-institution study from the US Sarcoma Collaborative.
predictors
radiation therapy
recurrence
retroperitoneal sarcomas
Journal
Journal of surgical oncology
ISSN: 1096-9098
Titre abrégé: J Surg Oncol
Pays: United States
ID NLM: 0222643
Informations de publication
Date de publication:
Dec 2019
Dec 2019
Historique:
received:
15
08
2019
accepted:
25
08
2019
pubmed:
6
9
2019
medline:
13
11
2019
entrez:
6
9
2019
Statut:
ppublish
Résumé
The use of radiation therapy in the treatment of retroperitoneal sarcomas has increased in recent years. Its impact on survival and recurrence is unclear. A retrospective propensity score matched (PSM) analysis of patients with primary retroperitoneal soft tissue sarcomas, who underwent resection from 2000 to 2016 at eight institutions of the US Sarcoma Collaborative, was performed. Patients with metastatic disease, desmoid tumors, and palliative resections were excluded. Total 425 patients were included, 56 in the neoadjuvant radiation group (neo-RT), 75 in the adjuvant radiation group (adj-RT), and 294 in the no radiotherapy group (no-RT). Median age was 59.5 years, 186 (43.8%) were male with a median follow up of 31.4 months. R0 and R1 resection was achieved in 253 (61.1%) and 143 (34.5%), respectively. Overall 1:1 match of 46 adj-RT and 59 neo-RT patients was performed using histology, sex, age, race, functional status, tumor size, grade, resection status, and chemotherapy. Unadjusted recurrence-free survival (RFS) was 35.9 months (no-RT) vs 33.5 months (neo-RT) and 27.2 months (adj-RT), P = .43 and P = .84, respectively. In the PSM, RFS was 17.6 months (no-RT) vs 33.9 months (neo-RT), P = .28 and 19 months (no-RT) vs 27.2 months (adj-RT), P = .1. Use of radiotherapy, both in adjuvent or neoadjuvent setting, was not associated with improved survival or reduced recurrence rate.
Sections du résumé
BACKGROUND
BACKGROUND
The use of radiation therapy in the treatment of retroperitoneal sarcomas has increased in recent years. Its impact on survival and recurrence is unclear.
METHODS
METHODS
A retrospective propensity score matched (PSM) analysis of patients with primary retroperitoneal soft tissue sarcomas, who underwent resection from 2000 to 2016 at eight institutions of the US Sarcoma Collaborative, was performed. Patients with metastatic disease, desmoid tumors, and palliative resections were excluded.
RESULTS
RESULTS
Total 425 patients were included, 56 in the neoadjuvant radiation group (neo-RT), 75 in the adjuvant radiation group (adj-RT), and 294 in the no radiotherapy group (no-RT). Median age was 59.5 years, 186 (43.8%) were male with a median follow up of 31.4 months. R0 and R1 resection was achieved in 253 (61.1%) and 143 (34.5%), respectively. Overall 1:1 match of 46 adj-RT and 59 neo-RT patients was performed using histology, sex, age, race, functional status, tumor size, grade, resection status, and chemotherapy. Unadjusted recurrence-free survival (RFS) was 35.9 months (no-RT) vs 33.5 months (neo-RT) and 27.2 months (adj-RT), P = .43 and P = .84, respectively. In the PSM, RFS was 17.6 months (no-RT) vs 33.9 months (neo-RT), P = .28 and 19 months (no-RT) vs 27.2 months (adj-RT), P = .1.
CONCLUSIONS
CONCLUSIONS
Use of radiotherapy, both in adjuvent or neoadjuvent setting, was not associated with improved survival or reduced recurrence rate.
Identifiants
pubmed: 31486096
doi: 10.1002/jso.25694
pmc: PMC6857791
mid: NIHMS1050586
doi:
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
1227-1234Subventions
Organisme : NCI NIH HHS
ID : P30 CA012197
Pays : United States
Organisme : NCI NIH HHS
ID : NCI CCSG P30CA012197
Pays : United States
Informations de copyright
© 2019 Wiley Periodicals, Inc.
Références
Int J Radiat Oncol Biol Phys. 2007 Jan 1;67(1):164-70
pubmed: 17084556
Ann Surg Oncol. 2015 Jan;22(1):256-63
pubmed: 25316486
Ann Surg Oncol. 2018 Mar;25(3):754-767
pubmed: 28895107
Lancet Oncol. 2016 Jul;17(7):966-975
pubmed: 27210906
Am J Clin Oncol. 2005 Jun;28(3):310-6
pubmed: 15923806
J Clin Oncol. 2002 Feb 1;20(3):791-6
pubmed: 11821462
Sarcoma. 2003;7(3-4):137-48
pubmed: 18521378
Eur J Cancer. 2001 Jun;37(9):1096-103
pubmed: 11378339
J Natl Compr Canc Netw. 2015 Nov;13(11):1366-74
pubmed: 26553766
Ann Oncol. 2014 Mar;25(3):735-42
pubmed: 24567518
J Oncol. 2008;2008:824036
pubmed: 19277103
Curr Treat Options Oncol. 2013 Sep;14(3):425-41
pubmed: 23649911
Ann Surg. 2015 Jul;262(1):163-70
pubmed: 25185464
Eur J Surg Oncol. 2015 Oct;41(10):1386-92
pubmed: 26251340
JAMA Oncol. 2018 Apr 1;4(4):483-492
pubmed: 29450452
J Natl Compr Canc Netw. 2018 May;16(5):536-563
pubmed: 29752328
Ther Adv Med Oncol. 2017 Jun;9(6):415-429
pubmed: 28607580
Sarcoma. 2018 Dec 5;2018:7972389
pubmed: 30631245